These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7578416)

  • 1. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.
    Fang B; Eisensmith RC; Wang H; Kay MA; Cross RE; Landen CN; Gordon G; Bellinger DA; Read MS; Hu PC
    Hum Gene Ther; 1995 Aug; 6(8):1039-44. PubMed ID: 7578416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
    Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
    Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.
    Xu L; Gao C; Sands MS; Cai SR; Nichols TC; Bellinger DA; Raymer RA; McCorquodale S; Ponder KP
    Blood; 2003 May; 101(10):3924-32. PubMed ID: 12531787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
    Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
    Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
    Kay MA; Landen CN; Rothenberg SR; Taylor LA; Leland F; Wiehle S; Fang B; Bellinger D; Finegold M; Thompson AR
    Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2353-7. PubMed ID: 8134398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes.
    Lozier JN; Thompson AR; Hu PC; Read M; Brinkhous KM; High KA; Curiel DT
    Hum Gene Ther; 1994 Mar; 5(3):313-22. PubMed ID: 8018746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
    Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
    Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
    Kay MA; Rothenberg S; Landen CN; Bellinger DA; Leland F; Toman C; Finegold M; Thompson AR; Read MS; Brinkhous KM
    Science; 1993 Oct; 262(5130):117-9. PubMed ID: 8211118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
    Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
    Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.
    Ehrhardt A; Xu H; Dillow AM; Bellinger DA; Nichols TC; Kay MA
    Blood; 2003 Oct; 102(7):2403-11. PubMed ID: 12805062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector.
    Brunetti-Pierri N; Nichols TC; McCorquodale S; Merricks E; Palmer DJ; Beaudet AL; Ng P
    Hum Gene Ther; 2005 Jul; 16(7):811-20. PubMed ID: 16000063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral vector-mediated gene therapy for hemophilia B.
    Eisensmith RC; Woo SL
    Thromb Haemost; 1997 Jul; 78(1):24-30. PubMed ID: 9198122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
    Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
    Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
    Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for hemophilia.
    Lynch CM
    Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.